Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
1231 Perindopril 4 mg and Indapamide 1.25 mg Tablet C09BA04-900-T10-01-XXX B Essential hypertension, for patients whose blood pressure is insufficiently controlled by perindopril alone. None One tablet daily, preferably taken in the morning and before a meal.
1232 Perindopril 4 mg Tablet C09AA04000T1001XX B i) Hypertension
ii) Stable coronary artery disease
iii) Heart failure		 i) & ii) Initial: 4mg once daily
Max. 8mg daily

iii) Initial: 2mg once daily
Maintenance: 4mg once daily

Dosing is individualised and according to product insert / protocol.
1233 Perindopril 8 mg Tablet C09AA04000T1002XX B i) Hypertension
ii) Stable coronary artery disease		 Initial: 2-4mg once daily
Maintenance: up to 8mg once daily

Dosing is individualised and according to product insert/protocol
1234 Perindopril Arginine 10mg, Indapamide 2.5mg & Amlodipine 10mg tablet C09BX01-935-T32-02-XXX A/KK As substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level. None 1 tablet a day
1235 Peritoneal Dialysis Solution (1.5% Dextrose) B05DB00908H2001XX B For chronic renal disease requiring dialysis and for acute renal failure Dose depending on clinical cases
1236 Peritoneal Dialysis Solution (4.25% Dextrose) B05DB00908H2002XX B For chronic renal disease requiring dialysis and for acute renal failure Dose depending on clinical cases
1237 Peritoneal Dialysis with 7.5% Icodextrin Solution B05DB00908H2003XX A* As a once replacement for a single glucose exchange as part of a continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) regimen for the treatment of chronic renal failure, particularly for patients who have lost ultra filtration on glucose solutions Administered as a single daily exchange for the long dwell in continuous ambulatory peritoneal dialysis or automated peritoneal dialysis. The recommended dwell time is 8 to 16 hours
1238 Permethrin 1% w/v Lotion. P03AC04000L6002XX B For topical treatment of head lice. Apply lotion onto clean towel dried hair ensuring every strand comes in contact with lotion for at least 10 minutes. Rinse completely. Re-apply after 10 days to ensure total recovery.
1239 Permethrin 5% w/v Lotion P03AC04000L6001XX A/KK Treatment of scabies None Apply thoroughly to all body parts from the head to soles of the feet, paying particular attention to all the folds and creases.

Leave medication on for 8 – 14 hours, and then wash off completely.
Not recommended for children less than 2 months of age.

Single application usually curative. May reapply after ONE week if live mites reappear.
1240 Perphenazine 4 mg Tablet N05AB03-000-T10-01-XXX B i) Treatment of psychotic disorders
ii) Used in the treatment of behavioural disorders in adults, in the aged and in children		 ADULT: Initially 4 mg 3 times daily adjusted according to response, maximum 24 mg daily.
ELDERLY: 1/4 to 1/2 adult dose.
CHILD: The lower range of the adult dosage may be used in children over 12. It should start with the smallest dose e.g 2mg, then titrate accordingly.
1241 Pertuzumab 420mg/14mL Concentrate for Solution for Infusion L01XC13-000-P33-01-xxx A* Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (node-positive) as part of a complete treatment regimen for early breast cancer. To be prescribed by Oncologist only The recommended initial dose of pertuzumab is 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30 to 60 minutes for up to 3 cycles.
1242 Pertuzumab/Trastuzumab 1200mg/600mg Solution for Subcutaneous Injection L01XY02-980-P30-02-xxx A* In combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (node positive) as part of a complete treatment regimen for early breast cancer. None The recommended initial dose of pertuzumab/trastuzumab is 1,200mg/600mg administered as an 8-minute subcutaneous injection, followed by 600mg/600mg administered every 3 weeks over approximately 5-minutes, for a total of 3 cycles.
1243 Pertuzumab/Trastuzumab 600mg/600mg Solution for Subcutaneous Injection L01XY02-980-P30-01-xxx A* In combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (node positive) as part of a complete treatment regimen for early breast cancer. None The recommended initial dose of pertuzumab/trastuzumab is 1,200mg/600mg administered as an 8-minute subcutaneous injection, followed by 600mg/600mg administered every 3 weeks over approximately 5-minutes, for a total of 3 cycles.
1244 Pethidine HCl 100 mg/2 ml Injection N02AB02110P3002XX B For relief of moderate to severe pain (medical and surgical), pre-anaesthetic medication and obstetrical analgesia ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
1245 Pethidine HCl 50 mg/ml Injection N02AB02110P3001XX B For relief of moderate to severe pain (medical and surgical), pre-anaesthetic medication and obstetrical analgesia ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
1246 Phenobarbitone (Phenobarbital) 200mg/ml Injection N03AA02-520-P30-01-XXX B All forms of epilepsy except absence seizures. None ADULT: 10 mg/kg IV at a rate of not faster than 100 mg/minute. Initial maximum dose does not exceeding 1 gm. Daily maintenance of 1 - 4 mg/kg/day.

CHILD: 3- 5mg per kg body weight as a single dose by intramuscular injection.
Dosing is according to product insert.
1247 Phenobarbitone (Phenobarbital) 30mg Tablet N03AA02-000-T10-02-XX B Epilepsy None ADULT: 60 - 180 mg daily on. CHILD: Up to 8 mg/kg daily
1248 Phenoxybenzamine HCl 100 mg/2 ml Injection C04AX02110P3001XX A* Hypertensive episodes associated with phaeochromocytoma 1 mg/kg daily over at least 2 hours into large vein. Do not repeat within 24 hours.
1249 Phenoxymethyl Penicillin 125mg Tablet J01CE02-500-T10-01-XXX C i) Treatment or prophylaxis of infections caused by susceptible organisms
ii) Prophylactic, rheumatic fever		 None i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly.
ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day
1250 Phenoxymethyl Penicillin 125mg/5ml Syrup J01CE02-500-F21-01-XXX C Treatment or prophylaxis of infections caused by susceptible organisms None CHILD: Up to 1 year: 62.5 mg 6 hourly; 1 - 5 years: 125 mg 6 hourly; 6 - 12 years: 250 mg 6 hourly
1251 Phenoxymethyl Penicillin 250mg Tablet J01CE02-500-T10-02-XXX C i) Treatment or prophylaxis of infections caused by susceptible organisms
ii) Prophylactic, rheumatic fever		 None i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly.
ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day
1252 Phenylephrine HCI 2.5% Eye Drops S01FB01-110-D20-01-XXX B For pupillary dilation in uveitis, for refraction without cyclopegic. For fundoscopy and other diagnostic procedures None Mydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary
1253 Phenytoin Sodium 100mg Capsule N03AB02-520-C10-02-XX B Control of tonic-clonic (grand mal) and psychomotor seizures None ADULT
Initial: 300mg daily in 3 equally divided doses
Maintenance: 300-400 daily in 3-4 equally divided doses
Max. dose: 600mg daily

CHILD
Initial: 5mg/kg/day in 2-3 equally divided doses
Maintenance: 4-8mg/kg/day
Max. dose: 300mg daily

Dosing is according to product insert.
1254 Phenytoin Sodium 125mg/5ml Suspension N03AB02-520-L80-01-XX B Control of tonic-clonic (grand mal) and psychomotor seizures None ADULT:
Initial: 125mg 2-3 times daily.
Max. dose: 625mg daily

CHILD:
Initial: 5mg/kg/day in 2-3 divided doses
Maintenance: 4-8 mg/kg/day in equally divided doses
Max. dose: 300mg daily

Dosing is according to product insert.
1255 Phenytoin Sodium 30mg Capsule N03AB02-520-C10-01-XX B Control of tonic-clonic (grand mal) and psychomotor seizures None ADULT
Initial: 300mg daily in 3 equally divided doses
Maintenance: 300-400 daily in 3-4 equally divided doses
Max. dose: 600mg daily

CHILD
Initial: 5mg/kg/day in 2-3 equally divided doses
Maintenance: 4-8mg/kg/day
Max. dose: 300mg daily

Dosing is according to product insert.
1256 Phenytoin Sodium 50mg/ml lnjection N03AB02-520-P30-01-XXX B i) Control of status epilepticus of the tonic-clonic (grand mal) type
ii) Prevention and treatment of seizures occurring during or following neurosurgery.		 None i) ADULT
Loading: 10-15mg/kg slow IV (max. 50mg per minute)
Maintenance: 100mg orally or IV every 6-8 hours

NEONATE & CHILD
Loading: 15-20mg/kg IV slow IV (max. 1-3mg/kg/minute)

ii) 100-200mg deep IM at approximately 4 hour intervals during surgery and continued postoperative.

Dosing is individualised and according to product insert / protocol.
1257 Pilocarpine 1% Eye Drops S01EB01-110-D20-01-XXX B Miotics in chronic open-angle glaucoma None 1 drop 1 - 4 times a day
1258 Pilocarpine 2% Eye Drops S01EB01-110-D20-02-XXX B Miotics in chronic open-angle glaucoma None 1 drop 1 - 4 times a day
1259 Pimecrolimus 1% cream D11AH02-000-G10-01-XXX A* Short-term and intermittent long-term therapy of mild to moderate atopic dermatitis in non-immunocompromised patients aged 2 years and older, in whom the use of alternative, conventional therapies are deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or intolerant of alternative, conventional therapies. i) First line for periorbital eczema;
ii) Second line for facial eczema.
 Apply a thin layer of the cream to the affected skin twice daily.
1260 Pine Tar, Coal Tar with Salicylic Acid (various concentrations) Solution D05AA00000L5202XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis Apply to the affected areas or as in product leaflet

Halaman-halaman